NSAIDs预防内镜逆行胰胆管造影术后胰腺炎的研究进展  

Recent advances in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with NSAIDs

作　　者：王钧[1] 白飞虎[2] 周毅[1] 

机构地区：[1]中国人民解放军第451医院消化内科,陕西省西安市710054 [2]宁夏医科大学附属医院消化内科,宁夏回族自治区银川市750004

出　　处：《世界华人消化杂志》2010年第13期1356-1359,共4页World Chinese Journal of Digestology

摘　　要：内镜逆行胰胆管造影术(endoscopic retrograde cholangiopancreatography,ERCP)已发展成为肝胆胰疾病的重要诊治手段,ERCP术后胰腺炎(post-ERCP pancreatitis,PEP)是ERCP术后最常见、最严重的并发症之一,常导致住院时间的延长,费用的增加,甚至危及患者的生命.已有多种药物用于预防PEP的发生,但研究结果均不能令人满意.非甾体类抗炎药(non-steroidal anti-inflammatory drugs,NSAIDs)是一类具有环氧合酶(cyclooxygenase)抑制活性药物的总称.近年来,NSAIDs在预防PEP中的作用已得到多项研究阳性结果支持,显示出了良好的应用前景,本文对这方面的研究进展作一综述.Acute pancreatitis is one of the most common complications of endoscopic retrograde cholan-giopancreatography （ERCP） and often results in prolonged hospitalization and further intervention. Trials of many pharmacological therapies for post-ERCP pancreatitis （PEP） have yielded disappointing results. Non-steroidal anti-inflam-matory drugs （NSAIDs） are potent inhibitors of prostaglandin synthesis,phospholipase A2 and neutrophil-endothelial interaction. Recently,prospective clinical trials evaluating NSAIDs in the prevention of PEP have yielded positive results,indicating their promising future in clinical use.

关 键 词：内镜逆行胰胆管造影术 胰腺炎 非甾体类抗炎药 

分 类 号：R657.4[医药卫生—外科学]